NHR (Neutrophil-to-HDL Cholesterol Ratio)

The Neutrophil-to-HDL Ratio (NHR) is an emerging biomarker that combines two key elements of cardiovascular health — inflammation and lipid balance — to provide a more complete picture of cardiovascular risk. It is calculated by dividing the number of neutrophils, one of the immune system’s first responders in inflammation, by the level of high-density lipoprotein cholesterol (HDL-C), known for its protective, anti-inflammatory, and antioxidant roles.

Neutrophils play a central role in inflammatory processes, releasing enzymes and reactive oxygen species that can damage the endothelium and accelerate plaque formation. HDL, on the other hand, helps counteract this by promoting cholesterol efflux, reducing oxidative stress, and protecting the vascular lining. The NHR therefore reflects the delicate balance between inflammatory burden and anti-inflammatory defense — when this balance tips toward inflammation, cardiovascular risk rises.

A higher NHR indicates increased neutrophil-driven inflammation alongside reduced HDL-mediated protection. This combination amplifies the risk of atherosclerosis, plaque instability, and coronary artery disease (CAD). Elevated NHR has been consistently linked to the presence and severity of CAD, even in patients whose LDL cholesterol appears well controlled. Studies show that individuals with high NHR are more likely to have multi-vessel CAD and face a greater risk of major adverse cardiovascular events (MACE) and long-term mortality.

Beyond chronic cardiovascular disease, NHR also carries strong prognostic value in acute settings. In patients with acute coronary syndrome (ACS) — particularly those with type 2 diabetes — higher NHR levels are associated with worse in-hospital outcomes and greater long-term mortality. These findings suggest that NHR not only identifies risk but can also reflect disease activity and recovery potential in real time.

Because inflammation is a shared pathway linking cardiovascular, metabolic, and systemic diseases, NHR also correlates with other inflammatory indices and predicts metabolic disorders such as insulin resistance and type 2 diabetes. In large population studies, elevated NHR has been tied to increased risk of arterial stiffness, aortic aneurysm, and atherosclerotic progression, underscoring its versatility as a marker of inflammation-driven vascular aging.

Traditional lipid ratios like the LDL to HDL ratio and LDL-C to ApoB ratio remain foundational in cardiovascular assessment, each offering insight into lipid-driven risk. The LDL/HDL ratio captures the balance between harmful LDL particles and protective HDL particles — higher ratios point to greater atherogenic potential. The LDL-C/ApoB ratio, by contrast, reflects LDL particle size: a low ratio indicates smaller, denser LDL particles that are more likely to penetrate vessel walls and trigger plaque formation.

What makes NHR distinct is its integration of inflammation into this equation. It not only accounts for lipid balance but also for the immune system’s activation state — a missing piece in many traditional lipid tests. Elevated NHR suggests that inflammation is actively undermining the protective role of HDL, which may help explain why some individuals develop cardiovascular events despite having “normal” cholesterol levels.

An elevated NHR signals that your body’s inflammatory response may be outweighing its anti-inflammatory protection. Addressing this requires a holistic approach that targets both immune regulation and lipid metabolism.

A diet rich in anti-inflammatory whole foods — such as extra-virgin olive oil, avocado, fatty fish, nuts, and deeply coloured vegetables — can help lower systemic inflammation and raise HDL levels. Limiting refined carbohydrates, processed meats, and industrial seed oils further reduces oxidative stress and immune activation. Regular exercise is one of the most effective ways to both increase HDL and reduce neutrophil-driven inflammation, while adequate sleep, stress reduction, and smoking cessation all play critical supporting roles.

If inflammation remains elevated, clinicians may consider testing for complementary biomarkers such as hs-CRP, ApoB, or LDL particle number, and evaluating for metabolic dysfunction, infections, or autoimmune triggers. Managing these underlying drivers can meaningfully reduce NHR and overall cardiovascular risk.

In summary, the NHR offers a powerful lens into the intersection of inflammation and lipid health. By understanding and improving this ratio, you’re not just lowering cholesterol — you’re actively restoring balance between the body’s defense systems and its vascular protection.

1. Ren, H., Zhu, B., Zhao, Z., et al. (2023). Neutrophil to high-density lipoprotein cholesterol ratio as the risk mark in patients with type 2 diabetes combined with acute coronary syndrome: A cross-sectional study. Scientific Reports, 13(1), 7836. https://doi.org/10.1038/s41598-023-35050-6
   

2. Liu, M., Liu, X., Wei, Z., et al. (2022). MHR and NHR but not LHR were associated with coronary artery disease in patients with chest pain with controlled LDL-C. Journal of Investigative Medicine, 70(7), 1501–1507. https://doi.org/10.1136/jim-2021-002314
   

3. Lamichhane, P., Agrawal, A., Abouainain, Y., Abousahle, S., & Regmi, P. R. (2023). Utility of neutrophil-to-high-density lipoprotein-cholesterol ratio in patients with coronary artery disease: A narrative review. Journal of International Medical Research, 51(4), 3000605231166518. https://doi.org/10.1177/03000605231166518
   

4. Tian, C., Wang, X., Tao, L., Chen, Y., & Tan, X. (2025). Association of neutrophil to high-density lipoprotein cholesterol ratio with aortic dissection and aneurysm risk: Insights from a UK Biobank cohort. BMC Public Health, 25(1), 886. https://doi.org/10.1186/s12889-025-22061-3
   

5. Chen, Y., Jiang, D., Tao, H., Ge, P., & Duan, Q. (2022). Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing PCI: A retrospective study. BMC Cardiovascular Disorders, 22(1), 434. https://doi.org/10.1186/s12872-022-02870-9
   

6. Yuan, S., Li, L., Pu, T., et al. (2024). The relationship between NLR, LDL-C/HDL-C, NHR and coronary artery disease.PLOS ONE, 19(7), e0290805. https://doi.org/10.1371/journal.pone.0290805